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Background: The purpose of this study was to assess the efficacy of oral valganciclovir in the 
treatment of anterior segment inflammation caused by cytomegalovirus (CMV) infection.
Methods: Consecutive patients with anterior segment inflammation due to CMV causing 
  anterior uveitis or corneal endotheliitis treated with oral valganciclovir were reviewed. Diagnosis 
of CMV infection was confirmed by polymerase chain reaction of the aqueous aspirate prior 
to commencement of oral valganciclovir. All patients were treated with an oral loading dose 
of 900 mg valganciclovir twice daily for at least 2 weeks, followed by an additional 450 mg 
valganciclovir twice-daily maintenance therapy. Changes in visual acuity, intraocular pressure 
(IOP), use of antiglaucomatous eye drops, and recurrence were analyzed.
Results: Thirteen eyes of 11 patients were followed for a mean of 17.2 months. Two patients 
had bilateral corneal endotheliitis. All eyes had absence of anterior segment inflammation 
within 3 weeks after treatment. Following treatment, the mean logMAR visual acuity improved 
significantly from 0.58 at baseline to 0.37 at the last follow-up (P = 0.048). The mean IOP and 
number of antiglaucomatous eye drops also decreased significantly (P = 0.021 and P = 0.004, 
respectively). Five (38.5%) eyes had recurrence of anterior uveitis after valganciclovir was 
stopped and required retreatment with oral valganciclovir.
Conclusion: Oral valganciclovir appeared to be effective in controlling CMV anterior uveitis, 
resulting in visual improvement and IOP reduction following control of inflammation. However, 
despite the initial clinical response in all cases, recurrence after cessation of oral valganciclovir 
could occur.
Keywords: cytomegalovirus infection, inflammation, anterior uveitis, endotheliitis, ocular 
hypertension, antiviral, valganciclovir
Introduction
In recent years, with the increasing use of polymerase chain reaction (PCR) for the 
detection of viruses in intraocular fluids, cytomegalovirus (CMV) infection is increasingly 
recognized as an important cause of anterior segment inflammation in immunocompetent 
individuals.1–5 Clinical features of CMV anterior segment inflammation in 
immunocompetent individuals include increased intraocular pressure (IOP), 
with anterior chamber inflammation like Posner-Schlossmann syndrome, iris 
atrophy with nodular endothelial changes similar to Fuchs uveitis syndrome, and 
corneal endotheliitis with coin-shaped keratic precipitates with or without corneal 
edema.6–10 Systemic and ocular antiviral therapies with ganciclovir are the main 
treatment options for CMV anterior segment inflammation.4,5,10–12 Valganciclovir, 
the prodrug of ganciclovir, is also available for convenient oral dosing instead of 
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intravenous ganciclovir.13,14 Most previous studies have only 
evaluated the short-term outcome of oral valganciclovir in 
the treatment of CMV anterior segment inflammation. The 
purpose of our study was to evaluate the long-term efficacy 
of oral valganciclovir in the treatment of CMV anterior 
segment inflammation.
Materials and methods
The study was a retrospective case series carried out at the 
Hong Kong Eye Hospital, Hong Kong. The case notes of all 
consecutive immunocompetent patients with CMV anterior 
segment inflammation who received oral valganciclovir 
treatment between June 2007 and August 2010 with a 
minimum follow-up duration of 6 months were reviewed. 
CMV anterior segment inflammation was defined as PCR-
confirmed CMV infection together with clinical features of 
Posner-Schlossmann syndrome, Fuchs uveitis syndrome, 
or corneal endotheliitis. Exclusion criteria included patients 
with human immunodeficiency virus infection, and those 
on systemic chemotherapy or immunosuppressants for 
internal organ transplantation or connective tissue disease. 
All patients received a loading dose of oral valganciclovir 
900 mg twice daily for at least two weeks, followed by 
maintenance therapy of valganciclovir 450 mg twice daily 
for at least 6 weeks. The study was performed in accordance 
with the tenets of the Declaration of Helsinki.
The main outcome measures of the study included 
baseline and final visual acuity, IOP measurements, use of 
antiglaucomatous drugs, and details of anterior segment 
inflammation on clinical examination, such as anterior 
chamber cells, presence of keratic precipitates, and iris 
atrophy.
Statistical analysis
Demographic characteristics of the patients are summarized 
by  descriptive  statistics  using  statistical  software 
(StatPlus:Mac 2009, AnalystSoft Inc, Vancouver, BC, 
  Canada). Comparisons of continuous variables were 
  performed using the Wilcoxon sign-ranked test and 
  comparison of categorical variables was performed using the 
Chi-squared test or Fisher Exact test. A P value of ,0.05 
was considered as statistically significant.
Results
Baseline demographics
A total of 13 eyes from 11 patients were included in the study 
(Table 1). Two patients had bilateral CMV anterior segment 
inflammation with corneal endotheliitis presented in both 
T
a
b
l
e
 
1
 
D
e
m
o
g
r
a
p
h
i
c
s
 
a
n
d
 
c
l
i
n
i
c
a
l
 
fi
n
d
i
n
g
s
 
o
f
 
1
1
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
c
y
t
o
m
e
g
a
l
o
v
i
r
u
s
 
a
n
d
 
a
n
t
e
r
i
o
r
 
s
e
g
m
e
n
t
 
i
n
fl
a
m
m
a
t
i
o
n
 
t
r
e
a
t
e
d
 
w
i
t
h
 
o
r
a
l
 
v
a
l
g
a
n
c
i
c
l
o
v
i
r
P
a
t
i
e
n
t
G
e
n
d
e
r
/
 
a
g
e
D
i
a
g
n
o
s
i
s
P
r
i
o
r
 
 
s
u
r
g
e
r
y
F
o
l
l
o
w
-
u
p
 
 
d
u
r
a
t
i
o
n
 
 
(
m
o
n
t
h
s
)
D
u
r
a
t
i
o
n
 
o
f
 
 
m
a
i
n
t
e
n
a
n
c
e
 
 
t
h
e
r
a
p
y
 
 
(
m
o
n
t
h
s
)
R
e
c
u
r
r
e
n
c
e
I
n
t
e
r
v
a
l
 
b
e
t
w
e
e
n
 
 
r
e
c
u
r
r
e
n
c
e
 
a
n
d
 
 
s
t
o
p
p
i
n
g
 
v
a
l
g
a
n
c
i
c
l
o
v
i
r
 
 
t
h
e
r
a
p
y
 
(
m
o
n
t
h
s
)
B
a
s
e
l
i
n
e
 
 
V
A
F
i
n
a
l
 
 
V
A
L
i
n
e
s
 
 
c
h
a
n
g
e
d
B
a
s
e
l
i
n
e
 
I
O
P
 
 
(
m
m
H
g
)
F
i
n
a
l
 
 
I
O
P
 
 
(
m
m
H
g
)
1
 
(
O
D
)
M
/
6
0
E
n
d
o
t
h
e
l
i
i
t
i
s
P
K
,
 
T
r
a
b
3
8
3
6
Y
e
s
4
2
0
/
7
0
2
0
/
8
0
0
-
1
2
2
1
1
4
1
 
(
O
S
)
M
/
6
0
E
n
d
o
t
h
e
l
i
i
t
i
s
P
K
,
 
T
r
a
b
3
8
3
6
n
o
n
/
A
2
0
/
8
0
0
2
0
/
7
0
+
1
2
8
9
2
 
(
O
D
)
F
/
5
0
E
n
d
o
t
h
e
l
i
i
t
i
s
n
o
n
e
1
3
3
.
5
n
o
n
/
A
2
0
/
1
0
0
2
0
/
4
0
+
4
3
0
1
2
2
 
(
O
S
)
F
/
5
0
E
n
d
o
t
h
e
l
i
i
t
i
s
n
o
n
e
1
3
3
.
5
n
o
n
/
A
2
0
/
3
0
2
0
/
2
0
+
2
1
2
1
6
3
M
/
5
7
E
n
d
o
t
h
e
l
i
i
t
i
s
T
r
a
b
2
4
2
n
o
n
/
A
2
0
/
1
6
0
0
2
0
/
2
0
+
1
8
1
6
1
7
4
M
/
5
9
F
U
S
n
o
n
e
1
2
2
Y
e
s
4
2
0
/
2
5
2
0
/
2
0
+
1
2
7
7
5
F
/
5
0
F
U
S
T
r
a
b
6
2
.
5
n
o
n
/
A
2
0
/
2
5
2
0
/
2
5
+
1
8
8
6
M
/
4
9
F
U
S
n
o
n
e
1
5
2
.
5
n
o
n
/
A
2
0
/
1
0
0
2
0
/
2
0
+
7
1
5
8
7
M
/
4
8
P
S
S
n
o
n
e
6
3
.
5
n
o
n
/
A
2
0
/
7
0
2
0
/
2
5
+
4
2
1
1
7
8
F
/
3
9
P
S
S
n
o
n
e
1
7
2
.
5
Y
e
s
1
2
0
/
3
0
2
0
/
3
0
+
0
2
3
1
6
9
M
/
5
8
P
S
S
P
h
a
c
o
,
 
T
r
a
b
2
3
3
.
5
n
o
n
/
A
2
0
/
7
0
2
0
/
8
0
0
-
1
2
1
8
6
1
0
M
/
2
8
P
S
S
n
o
n
e
6
7
Y
e
s
2
2
0
/
2
0
2
0
/
1
8
+
1
1
1
1
1
1
1
M
/
7
0
P
S
S
P
h
a
c
o
2
9
2
7
Y
e
s
1
2
0
/
7
0
2
0
/
2
5
+
4
2
8
1
1
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
M
,
 
m
a
l
e
;
 
F
,
 
f
e
m
a
l
e
;
 
P
S
S
,
 
P
o
s
n
e
r
-
S
c
h
l
o
s
s
m
a
n
n
 
s
y
n
d
r
o
m
e
;
 
F
U
S
,
 
F
u
c
h
s
 
u
v
e
i
t
i
s
 
s
y
n
d
r
o
m
e
;
 
P
K
,
 
p
e
n
e
t
r
a
t
i
n
g
 
k
e
r
a
t
o
p
l
a
s
t
y
;
 
T
r
a
b
,
 
t
r
a
b
e
c
u
l
e
c
t
o
m
y
;
 
P
h
a
c
o
,
 
p
h
a
c
o
e
m
u
l
s
i
fi
c
a
t
i
o
n
;
 
V
A
,
 
v
i
s
u
a
l
 
a
c
u
i
t
y
;
 
I
O
P
,
 
i
n
t
r
a
o
c
u
l
a
r
 
p
r
e
s
s
u
r
e
;
 
 
n
/
A
,
 
n
o
t
 
a
p
p
l
i
c
a
b
l
e
.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
596
Wong et alClinical Ophthalmology 2012:6
eyes at the same time. The mean age of the patients at the 
commencement of valganciclovir treatment was 51.6 ± 10.8 
(range 28–70) years, and there were eight males and three 
females. All patients were of Chinese ethnicity. Diagnoses 
included Posner-Schlossmann syndrome in five (45.4%) 
patients, Fuchs uveitis syndrome in three (27.3%) patients, 
and corneal endotheliitis in three (27.3%) patients.
All patients had aqueous aspiration performed prior 
to commencement of valganciclovir, and the PCR of the 
aqueous fluid was positive for CMV DNA and negative for 
herpes simplex virus and herpes zoster virus DNA. At time 
of starting oral valganciclovir, the mean ± standard   deviation 
logMAR visual acuity of the 13 eyes was 0.58 ± 0.57 
  (Snellen equivalent 20/76; range 0.0–1.8 logMAR units). 
The mean baseline IOP was 18.3 ± 7.4 (range 8–30) mmHg 
and the eyes were on a median three (range 0–4) types of 
antiglaucomatous eye drops prior to treatment with oral 
valganciclovir. Four (36.3%) patients were also on oral aceta-
zolamide for IOP control. Other topical medications used 
by the patients at presentation included 1% prednisolone 
acetate eye drops in seven patients, 0.5% loteprednol eta-
bonate eye drops in three patients, and 1% dexamethasone, 
neomycin, and polymyxin B combination eye drops in one 
patent. Six eyes had anterior chamber cells of 0.5+ or more 
at initial presentation, and keratic precipitates were seen in 
nine (69.2%) eyes. Five (38.5%) eyes had iris atrophy at 
baseline. Six (46.2%) eyes had previous surgery prior to the 
commencement of valganciclovir, including trabeculectomy 
(two eyes), keratoplasty (one eye), combined penetrating 
keratoplasty and trabeculectomy (one eye), phacoemulsi-
fication (one eye), and combined phacoemulsification and 
trabeculectomy (one eye).
Changes in anterior segment 
inflammation
The mean follow-up duration of the patients was 17.2 (range 
6–38) months. All patients received a loading dose of oral 
valganciclovir 900 mg twice daily for at least 2 weeks, with 
a median of 4 (range 2–9) weeks. This was followed by 
  maintenance therapy with oral valganciclovir 450 mg twice 
daily for 2–36 months. There was an absence of anterior 
  segment inflammation in all patients within 4 weeks following 
commencement of oral valganciclovir. Repeat aqueous tap 
was performed in five (45.5%) patients while they were tak-
ing valganciclovir, and the PCR for CMV was negative in all 
cases. Five (38.4%) eyes of five (45.5%) patients developed 
recurrence of anterior segment inflammation after stopping 
valganciclovir therapy. The median interval between stopping 
valganciclovir and recurrence of anterior segment inflam-
mation was 2 (range 1–4) months. Two of these patients had 
repeat aqueous tap and both were found to be positive for 
CMV PCR. All patients were resumed on oral valganciclovir 
following recurrence of anterior segment inflammation. Three 
patients remained on valganciclovir at the last follow-up, two 
for prevention of IOP rise in Posner-Schlossmann syndrome 
and one for prevention of graft failure in corneal endothe-
liitis. Eight eyes underwent subsequent surgery during the 
follow-up period, including trabeculectomy in three eyes, 
combined phacoemulsification and trabeculectomy in two 
eyes, phacoemulsification and endothelial keratoplasty in one 
eye, and phacoemulsification in one eye.
Changes in visual acuity  
and intraocular pressure
At the last follow-up, the mean logMAR visual acuity 
was 0.37 (Snellen equivalent 20/47). There was a signifi-
cant improvement in the level of visual acuity at the last-
  follow-up compared with baseline (Wilcoxon sign-ranked 
test, P = 0.048). The mean visual improvement was 2.3 
(range -12 to +18) lines. Two (15.4%) eyes lost three or 
more lines of vision, with one caused by failed corneal graft 
and the other due to bullous keratopathy.
For all 13 eyes in the study, the mean IOP at the final 
follow-up was 11.7 ± 4.0 (range 6–17) mmHg. The reduction 
in IOP compared with baseline was statistically significant 
(Wilcoxon sign-ranked test, P = 0.021). The median num-
ber of antiglaucomatous eye drops required per eye was 
0 (range 0–3) and the reduction from baseline was also sta-
tistically significant (Wilcoxon sign-ranked test, P = 0.004). 
None of the patients were on oral acetazolamide at the last 
follow-up.
There was no significant change in the mean IOP for the 
eight eyes which did not undergo trabeculectomy during 
the follow-up period (Wilcoxon sign-ranked test, P = 0.29). 
Nonetheless, the median number of antiglaucomatous eye 
drops for eyes which did not have trabeculectomy reduced 
significantly from three to one per eye following the use of 
oral valganciclovir (Wilcoxon sign-ranked test, P = 0.031).
Adverse events
During the follow-up period, none of the patients developed 
any systemic adverse event while taking oral valganciclovir. 
Blood tests, including complete blood count and renal   function 
test, were performed for all patients on oral   valganciclovir as 
standard-of-care and they remained normal throughout the 
course of valganciclovir treatment.
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illustrative case
A 70-year-old Chinese man (patient 11) was referred with 
increased IOP in his left eye and recurrent episodes of uveitis 
for 6 months, in a Posner-Schlossmann syndrome picture. He 
had a history of uneventful phacoemulsification, with intraoc-
ular lens implantation in both eyes performed two years 
previously. On initial presentation, his left eye visual acuity 
was 20/40. The left eye IOP was 20 mmHg   controlled with 
latanoprost, dorzolamide and timolol eye drops together 
with oral acetazolamide. Slit-lamp   examination of the left 
eye showed multiple fine pigmented keratic precipitates with 
1+ cells in the anterior chamber (Figure 1A). The posterior 
chamber intraocular lens was well centered in the capsular 
bag with no evidence of dislocation. In view of the clinical 
features of Posner-Schlossmann syndrome, aspiration of 
aqueous fluid was obtained for viral PCR and was positive 
for CMV . The oral acetazolamide was stopped and he was 
put on a course of oral valganciclovir 900 mg twice daily 
for 3 weeks followed by valganciclovir 450 mg twice daily 
for 2 months. Two weeks later, there was considerable 
reduction in keratic precipitates and anterior chamber cells, 
and left eye vision improved to 20/35, with IOP reduced to 
11 mmHg. At one month after starting valganciclovir, the 
keratic precipitates completely resolved, with absence of 
cells in the anterior chamber (Figure 1B). The left eye visual 
acuity improved further to 20/25 with an IOP of 10 mmHg. 
The antiglaucomatous eye drops were reduced to timolol 
only. Repeat aqueous aspirate for CMV PCR was negative 
at 3 months after starting valganciclovir and the oral valgan-
ciclovir was then stopped.
One month after stopping valganciclovir, the patient 
complained of blurring of vision in the left eye. His left eye 
visual acuity reduced to 20/30 and the left eye IOP raised 
to 28 mmHg. Slit-lamp examination showed recurrence of 
left eye anterior uveitis with pigmented keratic precipitates 
and 1+ cells in the anterior chamber (Figure 1C). Repeat 
aqueous aspiration was performed and the CMV PCR was 
positive. Oral valganciclovir was restarted at 450 mg twice 
daily, and 2 weeks later the anterior segment inflammation 
resolved completely (Figure 1D). His vision improved back 
to 20/25 and the left eye IOP reduced to 11 mmHg. The 
oral valganciclovir was maintained for 6 months with no 
recurrence of uveitis, and the IOP was controlled at around 
10 mmHg with timolol eye drops.
At 6 weeks after stopping valganciclovir for the second 
time, the patient again developed blurring of vision. The 
left eye visual acuity dropped to 20/50 and the IOP was 
32 mmHg. Slit-lamp examination showed left eye diffuse 
keratic precipitates with 1+ cells in the anterior chamber. He 
was restarted on valganciclovir 450 mg twice daily and the 
anterior segment inflammation again responded rapidly. Two 
weeks later, his left eye visual acuity improved to 20/30 and 
the IOP was 8 mmHg. The valganciclovir was maintained for 
over one year and there was no further recurrence of uveitis 
while the patient was on valganciclovir.
Discussion
Valganciclovir is a L-valyl ester prodrug of ganciclovir and 
provides excellent bioavailability following oral admin-
istration, with a plasma concentration similar to that of 
intravenous ganciclovir.14 It has been used to treat various 
ophthalmic disorders, including anterior uveitis,10–12 CMV 
retinitis,14,15 acute retinal necrosis,16 immune recovery uveitis 
with macular edema,17 recurrent corneal allograft failure,18 
and CMV corneal endotheliitis.19,20 Most of the studies pub-
lished on the use of oral valganciclovir for CMV anterior 
segment inflammation have only reported short-term efficacy, 
and its longer-term efficacy is unclear.
In our current study, we evaluated the use of oral 
valganciclovir for treating anterior segment inflammation 
caused by CMV infection, and all patients had a minimum 
follow-up period of 6 months. Our results demonstrated that 
all patients had a good response, with complete resolution 
of anterior segment inflammation following the use of oral 
valganciclovir. The findings are consistent with previous 
reports that valganciclovir is an effective treatment for 
Figure  1  Slit-lamp  photos  of  the  left  eye  of  a  patient  with  anterior  segment 
inflammation from cytomegalovirus. (A) Prior to commencement of valganciclovir, 
there were diffuse multiple pigmented keratic precipitates on the cornea. (B) Four 
weeks after valganciclovir therapy, the keratic precipitates completed resolved with 
absence of inflammation in the anterior chamber. (C) One month after stopping 
valganciclovir therapy, the was recurrence of keratic precipitates on the cornea 
with  mild  anterior  chamber  inflammation.  (D)  Two  weeks  after  recommencing 
valganciclovir, the keratic precipitates again resolved with no inflammation in the 
anterior chamber.
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anterior uveitis and corneal endotheliitis due to CMV 
infection.4,5,10–12,20 Moreover, the long-term efficacy appears 
to be favorable because patients have significant visual gain 
after treatment, with a significant IOP reduction due to 
control of inflammation. The number of antiglaucomatous 
eye drops required by the patient also reduced significantly 
when compared with baseline in both eyes with or without 
trabeculectomy performed. The increase in IOP caused by 
CMV infection is likely to be due to viral trabeculitis and 
obstruction of trabecular meshwork by inflammatory debris.4 
Therefore, the IOP can be controlled following control of 
anterior segment inflammation with antiviral therapy. The 
exact reason why some cases of CMV anterior segment 
inflammation develop an increase in IOP while others do not 
is unclear, but might be related to viral load or the extent of 
inflammation.
Several previous studies have demonstrated the efficacy 
of oral valganciclovir in treating anterior segment inflamma-
tion caused by CMV infection. Van Boxtel et al reported the 
outcomes for five patients with CMV anterior uveitis treated 
with oral valganciclovir for a mean duration of 8 (range 3–12) 
months.4 It was found that inflammation became quiescent 
within a few weeks following oral valganciclovir, and that 
the antiglaucomatous eye drops could be reduced shortly 
after treatment. However, recurrence was not uncommon 
and one patient had recurrence of uveitis despite having 
treatment for 12 months. Another patient also had recurrence 
when the dosage of valganciclovir was reduced. In another 
study by Chee et al, it was found that CMV infection was 
responsible for around 37.5% of patients with presumed 
Posner-Schlossmann syndrome and 31.3% of those with 
Fuchs heterochromic iridocyclitis.5 The authors also reported 
that all eyes responded well to the initial antiviral treatment, 
including oral valganciclovir or intravitreal ganciclovir, in 
terms of reducing inflammation and IOP control. However, 
77.7% of cases relapsed within eight months after stopping 
antiviral treatment.5
As with previously published series, we also observed a 
high recurrence rate of anterior segment inflammation after 
stopping oral valganciclovir therapy because 38.5% of eyes 
developed recurrence during the follow-up period. The 
main reason for the high recurrence rate of CMV infection 
after stopping therapy is that all anti-CMV drugs, including 
ganciclovir and valganciclovir, are virustatic and not 
virucidal.21 In order to reduce the recurrence rate of 
CMV anterior segment inflammation after cessation of 
valganciclovir, other forms of ganciclovir treatment such 
as intravitreal or topical treatment have been suggested.10,12 
Chee and Jap evaluated the use of systemic, topical, and 
intravitreal ganciclovir in 72 eyes from 70 patients with 
CMV anterior uveitis and found that topical ganciclovir 
gel had a moderate response rate but a lower recurrence 
rate compared with systemic or intravitreal ganciclovir.10 
Huang et al evaluated the use of intravitreal ganciclovir 
injection as a loading dose with or without subsequent 
oral valganciclovir to treat CMV anterior uveitis. Two 
patients had only the initial intravitreal ganciclovir injection 
without oral valganciclovir and four patients had a mean of 
2.3 months of oral valganciclovir after intravitreal treatment. 
The authors found that none of the patients had a recurrence 
of intraocular inflammation and all patients had significant 
improvement in visual acuity with significantly reduced IOP. 
Therefore, adding intravitreal ganciclovir might be a useful 
option in treating patients with CMV anterior uveitis. 
However, intravitreal ganciclovir frequently requires regular 
injections, and repeated intravitreal injections are associated 
with increased risks of intraocular infection, retinal break, 
and detachment. Because CMV anterior uveitis is less vision-
threatening compared with CMV retinitis, we only used oral 
valganciclovir to treat patients with CMV anterior segment 
inflammation in order to avoid the potential risks associated 
with intravitreal ganciclovir injections.
At present, there is no consensus on the standard 
treatment duration when using valganciclovir for managing 
patients with CMV anterior segment inflammation. Based 
on our series and previous studies,8–10,20 significant clinical 
improvements can be observed within 2–4 weeks after 
starting antiviral therapy and, therefore, an initial treatment 
duration of at least 6 weeks appears to be a reasonable choice. 
In our series, three patients were still on valganciclovir at 
the last follow-up due to multiple recurrences after stopping 
valganciclovir. One patient with corneal endotheliitis who had 
penetrating keratoplasty will likely remain on long-term oral 
valganciclovir therapy in order to prevent graft failure caused 
by recurrence of corneal endotheliitis. Two patients in our 
series developed visual loss due to graft failure and bullous 
keratopathy associated with CMV corneal endotheliitis. This 
emphasizes the need for early control of CMV infection in 
these patients. Further long-term studies will be useful in 
determining the optimal treatment regimen and duration of 
maintenance valganciclovir therapy in patients with CMV 
anterior segment inflammation.
In  summary,  our  study  demonstrated  that  oral 
valganciclovir is useful in controlling anterior segment 
inflammation secondary to CMV infection. With the control 
of inflammation, the drug is effective in reducing IOP and 
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the use of antiglaucomatous eye drops in these patients with 
CMV anterior segment inflammation. The main limitation 
of this study is its retrospective nature and the limited 
number of cases in the series, which prevented us from 
providing a definitive treatment recommendation for using 
oral valganciclovir for CMV anterior segment inflammation. 
Finding an alternative agent to replace oral valganciclovir 
might be useful in the long term due to the potential risk of 
systemic side effects associated with valganciclovir, such as 
neutropenia, anemia, and diarrhea.14,22 Nonetheless, none of 
the patients in our series developed any systemic adverse 
event associated with valganciclovir treatment. Another 
concern about oral valganciclovir therapy is the high cost of 
treatment because each 450 mg tablet of valganciclovir costs 
around US$30 and an initial 8 weeks of treatment will cost 
more than US$4000. Therefore, further studies to evaluate 
the role of other alternative forms of ganciclovir in treating 
patients with CMV anterior uveitis as a more cost-effective 
monotherapy or combination therapy are warranted.
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